NOD/SCID小鼠模型 z-bo 2020-12-01 436

　　Objective: To establish a NOD/SCID mouse model with human immunological characteristics and observe its immune response to triple-negative breast cancer. Methods: A total of 24 NOD/SCID mice without immune leakage were selected and divided into 4 groups. The immune reconstitution group was intraperitoneally injected with 250 mg/kg cyclophosphamide (CTX) 3 days in advance, and then injected with healthy human peripheral blood mononuclear cells ( PBMC) At the same time, human triple-negative breast cancer cells MDA-MB-231 were inoculated subcutaneously on the back; the immunization group was only injected with CTX and PBMC; the tumor-bearing group was only inoculated with MDA-MB-231; the blank control group was not treated. Regularly observe the biological and immunological characteristics of each group of mice. Results: The incubation period (10-12 d) of the immune tumor-bearing group was longer than that in the simple tumor-bearing group (8-10 d), and the growth rate of the tumor was slowed. The tumor volume at the fifth week was 1244.82±792.82 mm3 and 4308.77 mm3 (P<0.01 ), the survival rate is improved (P<0.01). Human IgG in peripheral blood of mice that received immune reconstitution could be detected in the second week and gradually increased, which was statistically significant compared with mice that did not receive immune reconstitution (P<0.01). The proportion of CD3+ cells in peripheral blood gradually decreased in the second week, but it was still detectable in the ninth week. At the 9th week, the proportion of CD3+ T cells in the spleen cells of mice was as high as 55.3% (immune tumor-bearing group) and 52.7% (simple tumor-bearing group). The spleen index of mice in the immune tumor-bearing group was 9.64 mg/g significantly higher than 3.82±0.31 mg/g in the immune-only group and 1.51±0.14 mg/g in the blank control group.

　　 Conclusion: Successfully constructed a stable NOD/SCID mouse model with human immunological characteristics, and observed its immune response to triple-negative breast cancer, which can provide an ideal animal model for triple-negative breast cancer immunotherapy research.